Mineralys Therapeutics, Inc. (MLYS) vs Progyny, Inc. (PGNY)
A side-by-side comparison of Mineralys Therapeutics, Inc. and Progyny, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
MLYS
Mineralys Therapeutics, Inc.
$21.94HealthcareDelayed quote: Oct 6, 2026, 3:50 PM EDT
PGNY
Progyny, Inc.
$25.93HealthcareDelayed quote: Oct 6, 2026, 3:50 PM EDT
Total return — MLYS vs PGNY
growth of $100 · dividends reinvested · last 4yMLYS +26.4% (+6.0%/yr)PGNY -17.5% (-4.7%/yr)MLYS compounded faster over this window
MLYS PGNY
MLYS vs PGNY: by the numbers
- •PGNY is the larger company ($2.03B vs $1.93B market cap).
- •PGNY is profitable (6.00% net margin) while MLYS runs a net loss (0.00%).
Metrics side by side
Valuation
| Metric | MLYS | PGNY |
|---|---|---|
| P/E ratio | N/A | 28.18 |
| Forward P/E | N/A | 20.16 |
| PEG ratio | N/A | 4.21 |
| P/S ratio | N/A | 1.55 |
| P/B ratio | 3.51 | 4.48 |
| EV / EBITDA | N/A | 15.96 |
| FCF yield | N/A | 10.73% |
Profitability
| Metric | MLYS | PGNY |
|---|---|---|
| Gross margin | 0.00% | 24.57% |
| Operating margin | 0.00% | 8.55% |
| Net margin | 0.00% | 6.00% |
| ROE | -63.45% | 17.35% |
| ROIC | -57.17% | 15.47% |
Growth (annualized)
| Metric | MLYS | PGNY |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 23.84% |
| EPS CAGR (5Y) | N/A | 4.72% |
| FCF CAGR (5Y) | N/A | 73.48% |
| Total return CAGR (5Y) | N/A | -14.83% |
Frequently asked
- Is MLYS or PGNY more profitable?
- PGNY runs the higher net margin — MLYS at 0.00% versus PGNY at 6.00%.
Go deeper
Dig into the metrics
Progyny P/E ratioMineralys Therapeutics ROEProgyny ROEMineralys Therapeutics operating marginProgyny operating marginMineralys Therapeutics revenue growthProgyny revenue growthMineralys Therapeutics free cash flowProgyny free cash flow
Mineralys Therapeutics & Progyny appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.